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test and, therefore, efforts have been made to find better 
biomarkers [3]. 
Some biomarkers have been developed to estimate the 
glomerular filtration rate (GFR) and detect declining 
kidney function. However, there is still a lack of simple 
tools to detect trends in renal function over time, when 
the GFR is normal or high [3]. Cystatin C is a low-
molecular weight endogenous protein, produced at a 
steady rate by nucleated cells and eliminated from the 
 
ABstrACt
Introduction: Diabetic nephropathy is a frequent and dreaded complication of diabetes mellitus. The purpose of this 
work was to study the role of serum cystatin C in the early detection of diabetic nephropathy among type 2 diabetic 
patients. 
Methods: This was a cross-sectional study conducted in Cotonou over a period of six months. Blood samples were 
tested at the regional food safety testing analysis laboratory. Type 2 diabetic patients older than 15 years, who gave 
their informed consent, were included in the study. Patients with proven proteinuria, acute kidney injury, haematuria, 
a positive urine test for nitrite, or reduced glomerular filtration rate <60 mL/min/1.73 m2 were excluded from the 
study. All patients were subjected to serum cystatin C and microalbuminuria assays. 
Results: Eighty-eight patients were included in the study. Their average age was 50.7 ± 9.6 years and the male to 
female ratio was 1.4:1. Twenty-four-hour microalbuminuria was positive in 53 (60%) cases whereas serum cystatin 
C tested positive in only 2 cases. Sensitivity and specificity tests applied to cystatin C showed very low sensitivity 
(4%) with a positive predictive value of 100% and high specificity (100%) with a negative predictive value of 41%. 
Conclusions: When compared with 24-hour microalbuminuria, serum cystatin C assay was not sensitive enough to 
prove suitable for screening for diabetic nephropathy. Serum cystatin C would therefore not be useful for the early 
detection of nephropathy among type 2 diabetic patients.
Keywords: Benin; cystatin C; CKD screening; microalbuminuria; diabetic nephropathy.
INtrODUCtION
Diabetic nephropathy (DN) is a form of progressive 
chronic kidney disease and one of the most frequent and 
dreaded complications of diabetes mellitus [1]. This com-
plication could be prevented by appropriate treatment 
following early detection, particularly among type 2 
diabetic patients. Early detection is often based on 24-
hour microalbuminuria bioassays [2] and this is of great 
therapeutic and prognostic importance. However, in 
some cases, kidney disease is not detected through this 
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body by glomerular filtration and subsequent proximal 
tubular reabsorption and degradation [4]. It is a potentially 
useful biomarker when the glomerular filtration rate is still 
normal or only slightly reduced [5,6]. 
Several equations have been established to estimate the 
GFR based on serum cystatin C [7-10]. The predominance 
of these formulae over those derived from the Modifica-
tion of Diet in Renal Disease (MDRD) study is not proven 
[10,11] among type 2 diabetic patients. In about 20 diabetic 
patients, Rigalleau et al. observed a significant correlation 
between glomerular filtration rate determined through 
radioisotope methods and GFR estimated using cystatin 
C-based equations [12]. There is less bias with cystatin 
C-based equations than with the MDRD equation. Indeed, 
they are more useful for follow-up of renal function as 
suggested by a longitudinal study on type 2 diabetes [3]. 
Cystatin C offers improvements in the estimation of the 
GFR among diabetic patients, but requires standardiza- 
tion [13,14].
Among type 2 diabetic patients, cystatin C as a biomarker 
has been compared to creatinine-based methods to esti-
mate GFR, but very few studies have compared it to 
microalbuminuria for the detection of DN. Our overall 
objective was to study the role of serum cystatin C in the 
early detection of diabetic nephropathy among type 2 
diabetic patients, using microalbuminuria assessed on 24-
hour urine collection as our reference standard.
MEtHODs
This cross-sectional study was conducted over a period of 
six months, from April to September 2014, at the Cotonou 
Insulin Bank, where patient recruitment as well as blood 
and urine sampling were undertaken. Samples were 
handled at the Biochemical Department of the regional 
food safety testing analysis laboratory at the Regional 
Institute of Industrial Engineering, Biotechnology and 
Applied Sciences (IRGIB-Africa).
We included all type 2 diabetic patients aged above 15 
years who consented to participate in the study. We 
excluded all patients with proven proteinuria, haematuria, 
positive urine test for nitrite, reduced GFR <60 mL/
min/1.73 m2, congestive heart failure, prostate disease, 
malignancy or infection. Each patient was given a simplified 
and schematic explanation of the 24-hour urine collection 
procedure.
All patients were subjected to 24-hour microalbuminuria 
and serum cystatin C measurement. Microalbuminuria was 
determined by immuno-chromatography on freshly col-
lected urine. The normal value is less than 30 mg/24 h and 
microalbuminuria was considered present when it was ≥30 
mg/24 h and ≤300 mg/24 h on two samples obtained one 
month apart. The serum cystatin C concentration was 
measured through sandwich ELISA. Serum samples were 
stored at –20°C and measurements made in a single batch. 
The normal value of serum cystatin C is between 7.8–500 
ng/mL. It is considered as raised when ≥500 ng/mL.
In addition, socio-demographic variables (age, gender, pro-
fession, place of origin), history (hypertension, family 
history), clinical data (body mass index, weight) and 
laboratory data (blood glucose and serum creatinine) were 
all recorded. 
The data were entered, processed and analysed using SPSS 
16.0. Sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of serum cystatin C 
were calculated using the microalbuminuria test as the gold 
standard. Statistical significance was set at <5% and 95% 
confidence intervals were calculated.
rEsULts
The study population included 88 patients. Their socio-
demographic characteristics are summarized in Table 1. 
Patients’ ages ranged from 21–75 years, with a mean age of 
50.7 ± 9.6 years. Women comprised 58% and all the 
patients were urban residents. 
Diabetic nephropathy, as diagnosed by the presence of 
microalbuminuria, was present in 53 of the 88 patients 
(60.2%). Elevated cystatin C concentrations were present 
in 2 patients (2.3%); these patients also demonstrated 
microalbuminuria. The sensitivity of the cystatin C test was 
3.8%, and the specificity 100%. The PPV was 100% and the 
NPV 40.7%.
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table 1.  Socio-demographic characteristics of patients with 
type 2 diabetes.
Total (n = 88)     Percentage (%)
Age
< 45                                                                     20 22.72
45–50 21                            23.86
50–55 18 20.45
≥ 55                                             29 32.95
Gender  
Male                                            37 42.00
Female                                         51 58.00
Place of residence
Cotonou                                       88 100.00
Level of education
Completed school                          26 29.50
Primary education                       17 19.30
Secondary education                   33 37.50
Tertiary education/University 12 13.60
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DIsCUssION
A large proportion of our study population had diabetic 
nephropathy as assessed by our gold standard, micro-
albuminuria. However, the cystatin C-based test to estimate 
GFR had very low sensitivity for detecting the affected 
patients and therefore cannot be used for the early 
diagnosis of diabetic nephropathy when the GFR would be 
expected to be near-normal, or even elevated.
Diabetic patients should have annual tests for micro-
albuminuria as recommended by the Diabetes Associa- 
tion and the National Kidney Foundation [15-17]. 
Microalbuminuria is a risk marker for both cardiovascular 
disease and renal dysfunction among type 2 diabetic 
patients [15,18]. In 2015, Agboton et al. reported a 24-
hour microalbuminuria frequency of 47.5% in type 2 
diabetic patients in southern Benin [19]. The frequencies 
of various hospital-based studies range from 10.3% to 
57.3% [18,20]. 
Ali et al. reported a prevalence of 16.1% among type 2 
diabetic patients in Iraq [21], whereas Berrada et al. 
reported a frequency of 65% [22]. Other studies from 
Pakistan, India and Tanzania reported prevalences ranging 
from 20% to 61% [23-25]. In a literature review on the 
prevalence of diabetic nephropathy among type 2 diabetic 
patients in some Arab countries, Aldukhayel reported a 
prevalence ranging from 1.2% to 61.2% [26].
Of our 88 diabetic patients, serum cystatin C was raised 
amongst only two. Our study excluded patients with GFR 
<60 mL/min/1.73 m2 and also included very few elderly 
patients. In studies where patients with all levels of renal 
function are included, the prevalence of nephropathy based 
on cystatin C would be expected to be much higher [27].
Compared to creatinine, cystatin C has been reported in 
some studies to be a more sensitive marker for the 
estimation of GFR among type 2 diabetics [14], whereas 
other studies found it to be less sensitive in detecting early 
kidney failure among diabetic patients [28]. Wang et al. 
have shown that serum cystatin C was positively correlated 
with microalbuminuria and increased with the progression 
of diabetic nephropathy [29]. Furthermore, Mueller et al. 
demonstrated that cystatin C does not detect acute 
changes of GFR and is not useful in assessing renal functional 
reserve [30].
CONCLUsIONs
Our study found that the ability of serum cystatin C 
measurements to diagnose diabetic nephropathy at an 
early stage was poor. It therefore cannot be recommended 
as a screening test in those patients who would be expected 
to have normal or near-normal GFR.
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